Eenhancement of solubility and dissolution rate of Furosemide by ternary solid dispersion technique by Gahandule, Mangal & Gadhave, V. M.
  
Research Article 
 
Eenhancement of solubility and dissolution rate of Furosemide by 
ternary solid dispersion technique 
 
Gahandule Mangal* and Gadhave M. V 
 
Advanced Quality Assurance Technique Department, Vishal Institute of Pharmaceutical Education and Research, Ale, India 
 
*Correspondence Info: 
Gahandule Mangal,  
Advanced Quality Assurance Technique 
Department, Vishal Institute of 
Pharmaceutical Education and Research, 
Ale, India 
E-mail: 
mangalgahandule1993@gmail.com   
      
Keywords:  
Furosemide,   
solid dispersion,  
poloxamer 407,  
pvpk30, 
PEG 6000,  
DSC, 
XRD,  
In vitro dissolution study 
 
 
 
 
1. Introduction 
Solid dispersions can be defined as molecular or amorphous mixtures of poorly water soluble drugs in hydrophilic 
carriers in which the polymer properties play an important role in the drug dissolution profile. It has been estimated that 
40% of new chemical entities being discovered are poorly water-soluble. With recent advances in screening methods for 
identifying potential drug candidates, an increasing number of poorly water soluble drugs have been identified as potential 
therapeutic agents. Unfortunately, these drugs have poor bioavailability due to their poor solubility. This has limited the 
commercial potential of these drugs. The solid dispersion technique is one of the most efficacious to improve the 
bioavailability of drugs with low water solubility. Among the important factors increasing the solubility of drugs in solid 
dispersions, particle size reduction, reduced agglomeration, improved wettability and solubility, or dispersion of the drug as 
micro-fine crystals, amorphous materials or in a molecular form must be mentioned. These formulations offer many 
advantages over others and the most relevant are the lower cost of the adjuvants and the feasible industrial application. 
Solid dispersion in an inert carrier or matrix of solid state prepared mainly by the melting (or fusion) and solvent 
evaporation methods. The melting method involves heating a physical mixture of an active agent and a carrier until melted, 
followed by rapidly solidifying under vigorous mixing, resulting in super saturation of the drug by instantaneous 
solidification. On the other hand, the solvent evaporation method involves dissolving a physical mixture of two or more 
chemicals in a common solvent, followed by evaporation of the solvent. The proper selection of solvent and its removal rate 
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are crucial in determining the quality of the final dispersion. The release mechanism of drug from a variety of solid 
dispersions depends on the physical properties of carriers as well as drug substances and preparation methods. 
Furosemide (FRMD) is 5-(aminosulphonyl)-4-chloro-2-[(2-fuanyl-methyl) amino] benzoic acid, a potent high 
ceiling (loop) diuretic, mainly used in the treatment of hypertension.2 The drug has been classified as class IV drug as per 
the biopharmaceutical classification system (BCS) and having low solubility and oral bioavailability, one of the major cause 
of the low oral bioavailability of FRMD is its solubility.8,9 Furosemide, a loop diuretic, inhibits water reabsorption in the 
nephron by blocking the sodium-potassium-chloride cotransporter (NKCC2) in the thick ascending limb of the loop of 
Henle. This is achieved through competitive inhibition at the chloride binding site on the cotransporter, thus preventing the 
transport of sodium from the lumen of the loop of Henle into the basolateral interstitium. Consequently, the lumen becomes 
more hypertonic while the interstitium becomes less hypertonic, which in turn diminishes the osmotic gradient for water 
reabsorption throughout the nephron. Because the thick ascending limb is responsible for 25% of sodium reabsorption in 
the nephron, furosemide is a very potent diuretic. The objective of the present study was to improve the solubility of FRDM 
by using eudragit polymer in three different ratio. The formulations were characterized by in vitro dissolution study to 
compare the effects of polymers on the preparation of solid dispersion and dissolution enhance.[1-5] 
 
2. Material and Method 
Furosemide is purchase for gift sample of Sanofi Aventis Andheri Mumbai, All other materials used were of 
pharmaceutical or analytical grade. 
Instruments:- Schemadzu UV-vis spectrophotometry model 1800, laboratory, Perkin Emer Spectrum 68 FTIR, Dissolution 
tester (USP) TDT-08L (Electrolab), 
2.1 Preparation of solid dispersion by solvent evaporation method [6] 
Required amount of furosemide was dissolved in 20 ml of methanol. Accurately weighed carrier corresponding to 
different drug: carrier ratio by weight was dispersed in drug solution. Then the solvent was allowed to evaporate 
completely. The resulting solid mass was then pulverized in a mortar to get dry free-flowing powder. The powder was 
passed through a #80 mesh sieve. The resulting mass was transferred to desiccators containing CaCl2 and stored until 
completely dry. Solid dispersion of furosemide with polymers in the ratio (1:1:1, 1:2:2, 1:3:3, 1:4:4 and 1:5:5 resp.) was 
prepared. 
 
Table 1: Formulation table of furosemide solid dispersion 
Drug Furosemide Furosemide Furosemide 
Carrier PEG6000:POLOXAMER 407 POLOXAMER407:PVPK30 PEG6000:PVPK30 
SSD1 1:1:1 1:1:1 1:1:1 
SSD2 1:2:2 1:2:2 1:2:2 
SSD3 1:3:3 1:3:3 1:3:3 
SSD4 1:4:4 1:4:4 1:4:4 
SSD5 1:5:5 1:5:5 1:5:5 
 
2.2 Preparation of solid dispersion tablet [7-10] 
All ingredients weighed and materials except Talc and Magnesium Stearate were passed through sieve no. 40. 
Prepared blend was lubricated with Talc and Magnesium Stearate which was previously passed through sieve no. 80. 
Tablets were compressed using on BB tooling Compression machine. Tablet weight was maintained as per the solid 
dispersion polymer drug ratio. In addition to one or multiple filler binders and drug substances, generally a disintegrant, a 
lubricant and substance such as glidants are present in the tablet formulation. 
 
Table 2:-Formulation of solid dispersion tablet 
Sr no Name of ingredients Quantity required  (mg) 
1) Furosemide 12 
2) Starch 8 
3) Avicel ph 102 82 
4) Magnesium stearate 0.5 
5) Talc 0.5 
Total weight of the tablet - 100mg. 
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2.3 Evaluation Parameter of Solid Dispersion Tablet 
1) % Practical Yield: [10,15]
 
Percentage practical yield is calculated to know about percent yield or efficiency of any method, thus its help in 
selection of appropriate method of production. Solid dispersions were collected and weighed to determine practical yield 
(PY) from the following equation. 
 
Practical Mass (Solid dispersion) 
PY(%) = ----------------------------------------- × 100 
Theoretical Mass (Drug + carrier) 
 
2) Drug content: [11,15]
 
10 mg of solid dispersions were weighed accurately and dissolved in 10 ml of methanol. The solution was filtered, 
diluted suitably and drug content was analyzed at 238 nm by UV spectrophotometer. Each sample analyzed in triplicate. 
Actual drug content was calculated for all batches using the equation as follows: 
 
Tact 
Drug content %   = -------- ×100 
Tss 
 
                                                Actual Simvastatin content in weight quantity of solid dispersion 
= -------------------------------------------------------------------------------- × 100 
                                                         Theoretical amount of Simvastatin in solid dispersion 
 
3) In Vitro dissolution study: [12,15]
 
Dissolution studies were performed assuring sink condition according to the paddle method (USP) using USP 
XXIII apparatus type‐II (electrolab TDTO9T). The dissolution medium was 900 ml 0.1N HCl kept at 37°C ± 0.5°C. The 
solid dispersions containing 100 mg of Simvastatin was taken in a muslin cloth and tied to the rotating paddle kept in the 
basket of dissolution apparatus, the paddle was rotated at 50 rpm. Samples of 5 ml were withdrawn at specified time 
intervals and analyzed spectrophotometrically at 276 nm using Shimadzu‐1800 UV‐visible spectrophotometer. The samples 
withdrawn were replaced by fresh buffer solution. Each preparation 
was tested in triplicate and then mean values were calculated. 
4) Fourier transform infrared (FTIR) spectroscopy 
FTIR spectra were recorded on samples prepared in potassium bromide (KBr) disks using a Shimadzu Corporation 
(Koyto, Japan) facilty (model - 8400S). Samples were prepared in KBr disks in a hydrostatic press at 6-8 tons pressure. The 
scanning range was 500 to 4000 cm -1. 
5) Differential scanning calorimetry (DSC): [13,15]
 
Thermal analysis of Simvastatin, PVP K30 and the solid dispersion were carried out using differential scanning 
calorimetry method. Samples were examined using a Shimadzu TGA‐ 50 DSC instrument. 
Samples equivalent to approximately 8 mg Simvastatin were placed in aluminum pans and heated from 40 to 
250°C with a heating rate of 10°C/min.  
6) X-ray Powder Diffraction (XRD): [14-17]
 
Furosemide was assessed by carrying out physical state analysis. The cavity of the metal sample holder of X ray 
diffractometer was filled with ground Sample powder & then smoothed out with a spatula. 
X-ray Diffraction pattern of Simvastatin was obtained using the X-ray Diffractometer (Siemens‟, Germany D-
5000). 
 
3. Result and Discussion 
Solid dispersions of Simvastatin were prepared by different methods using carriers like PEG 6000 and Poloxamer 
407. In the present work, total 15 formulations were prepared and their complete composition is shown in Table‐2. All the 
Solid dispersions prepared were found to be fine and free flowing powders. 
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Table 3: Result of percentage yield, & Drug content and in vitro dissolution of solid dispersion of furosemide 
Sr. No Formulation code % practical yield Drug content % drug release 60min 
1 SSD-A1 74.75 41.40 56.29 
2 SSD-A2 74.3 45.26 77.24 
3 SSD-A3 76.85 43.36 77.23 
4 SSD-A4 73.47 40 69.34 
5 SSD-A5 68.18 37.1 80.62 
6 SSD-B1 63 64.4 71.88 
7 SSD-B2 84.2 55 66.40 
8 SSD-B3 61.53 58.83 58.00 
9 SSD-B4 88.47 82 82.71 
10 SSD-B5 79.88 38 81.66 
11 SSD-C1 73.33 41.60 56.66 
12 SSD-C2 81.4 46 62.63 
13 SSD-C3 87.82 78 65.72 
14 SSD-C4 82.22 81.33 75.11 
15 SSD-C5 76.56 76.34 82.46 
1) Percent practical yield 
The results of percent practical yield studies are shown in Table No. 3 .The % Practical yield of the prepared solid 
dispersions was found to be in the range of 61.53- 88.47 % The maximum yield was found 88.47 % in SSD- B4 
formulation. 
2) Drug content 
The actual drug content of all the 15 formulations are shown in Table No. 3 .The drug content of the prepared 
Solid dispersions were in the range of 40‐ 82 % indicating the application of the present methods for the preparation of 
Solid dispersions with high content uniformity. The maximum % drug content was found 82 % in SSD-B4 formulation. 
3) In vitro dissolution study 
Solid dispersion prepared by solvent evaporation method shows improved dissolution at the end of 60 min which 
is 82.71%. The ratio Drug: Poloxamer 407: pvp k30 (1:4:4) showed better in vitro release when compared with that of pure 
drug which is 28.78 % at the end of 60min. The solid dispersion prepared by solvent evaporation method and showed 1.5 
fold increases in dissolution. This is due to increased wet ability and dispersibility of drug by the carrier. Hydrophilic carrier 
will help to improve wetting property and reduce the interfacial tension between hydrophobic drug and dissolution medium. 
The increase in dissolution rate was in the order of Poloxamer 407: pvpk30 > Poloxamer 407: PEG 6000 > PEG 6000: PVP 
K30. 
Table 4: Caliberation of furosemide 
Concentration Absorption 
5 0.5895 
10 0.9382 
15 1.232 
20 1.564 
25 1.876 
 
 
Fig 1: Calibration of furosemide 
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Table 5:-% drug release calculation 
A1 Formulation batch 
PEG6000: 
PVPK30  
(1:1:1) 
      
Time abs slope intercept conc conc*900 conc*10 conc/1000 % drug release 
5 0.4432 0.064 0.28 2.55 2295 22950 22.95 38.25 
10 0.4897 0.064 0.28 3.276563 2948.906 29489.06 29.48906 49.14844 
15 0.5234 0.064 0.28 3.803125 3422.813 34228.13 34.22813 57.04688 
30 0.532 0.064 0.28 3.9375 3543.75 35437.5 35.4375 59.0625 
45 0.5785 0.064 0.28 4.664063 4197.656 41976.56 41.97656 69.96094 
60 0.5543 0.064 0.28 4.285938 3857.344 38573.44 38.57344 64.28906 
       
Avg= 56.29297 
 
1:2:2 A2 BATCH 
Time Abs slope intercept conc conc*900 conc*10 conc/1000 % drug release 
5 0.5342 0.064 0.28 3.971875 3574.688 35746.88 35.74688 59.57813 
10 0.543 0.064 0.28 4.109375 3698.438 36984.38 36.98438 61.64063 
15 0.5949 0.064 0.28 4.920313 4428.281 44282.81 44.28281 73.80469 
30 0.654 0.064 0.28 5.84375 5259.375 52593.75 52.59375 87.65625 
45 0.6648 0.064 0.28 6.0125 5411.25 54112.5 54.1125 90.1875 
60 0.6665 0.064 0.28 6.039063 5435.156 54351.56 54.35156 90.58594 
        
77.24219 
 
1:3:3 A3 BATCH 
Time Abs slope intercept conc conc*900 conc*10 conc/1000 %drug release 
5 0.498 0.064 0.28 3.40625 3065.625 30656.25 30.65625 51.09375 
10 0.498 0.064 0.28 3.40625 3065.625 30656.25 30.65625 51.09375 
15 0.598 0.064 0.28 4.96875 4471.875 44718.75 44.71875 74.53125 
30 0.6754 0.064 0.28 6.178125 5560.313 55603.13 55.60313 92.67188 
45 0.689 0.064 0.28 6.390625 5751.563 57515.63 57.51563 95.85938 
60 0.6987 0.064 0.28 6.542188 5887.969 58879.69 58.87969 98.13281 
        
77.23047 
 
1:4:4 A4 BATCH 
time Abs slope intercept conc conc*900 conc*10 conc/1000 %drug release 
5 0.4675 0.064 0.28 2.929688 2636.719 26367.19 26.36719 43.94531 
10 0.4898 0.064 0.28 3.278125 2950.313 29503.13 29.50313 49.17188 
15 0.5122 0.064 0.28 3.628125 3265.313 32653.13 32.65313 54.42188 
30 0.5987 0.064 0.28 4.979688 4481.719 44817.19 44.81719 74.69531 
45 0.689 0.064 0.28 6.390625 5751.563 57515.63 57.51563 95.85938 
60 0.698 0.064 0.28 6.53125 5878.125 58781.25 58.78125 97.96875 
        
69.34375 
 
1:5:5 A5 BATCH 
time Abs slope intercept conc conc*900 conc*10 conc/1000 %drug release 
5 0.4532 0.064 0.28 2.70625 2435.625 24356.25 24.35625 40.59375 
10 0.598 0.064 0.28 4.96875 4471.875 44718.75 44.71875 74.53125 
15 0.6543 0.064 0.28 5.848438 5263.594 52635.94 52.63594 87.72656 
30 0.6654 0.064 0.28 6.021875 5419.688 54196.88 54.19688 90.32813 
45 0.675 0.064 0.28 6.171875 5554.688 55546.88 55.54688 92.57813 
60 0.698 0.064 0.28 6.53125 5878.125 58781.25 58.78125 97.96875 
        
80.62109 
  
 
 
International Journal of Advances in Pharmaceutics 5 (6) 2016                                                                                 145 
 
 
B1 BATCH 
POLO 
407:PVPK30 
1:1:1 
       
Time abs slope intercept conc conc*900 conc*10 conc/1000 %drug release 
5 0.4231 0.064 0.28 2.235938 2012.344 20123.44 20.12344 33.53906 
10 0.5432 0.064 0.28 4.1125 3701.25 37012.5 37.0125 61.6875 
15 0.567 0.064 0.28 4.484375 4035.938 40359.38 40.35938 67.26563 
30 0.654 0.064 0.28 5.84375 5259.375 52593.75 52.59375 87.65625 
45 0.6654 0.064 0.28 6.021875 5419.688 54196.88 54.19688 90.32813 
60 0.6675 0.064 0.28 6.054688 5449.219 54492.19 54.49219 90.82031 
        
71.88281 
 
1:2:2 B2 BATCH 
Time Abs slope intercept conc conc*900 conc*10 conc/1000 %drug release 
5 0.6523 0.064 0.28 5.817188 5235.469 52354.69 52.35469 87.25781 
10 0.5776 0.064 0.28 4.65 4185 41850 41.85 69.75 
15 0.554 0.064 0.28 4.28125 3853.125 38531.25 38.53125 64.21875 
30 0.5213 0.064 0.28 3.770313 3393.281 33932.81 33.93281 56.55469 
45 0.5473 0.064 0.28 4.176563 3758.906 37589.06 37.58906 62.64844 
60 0.5275 0.064 0.28 3.867188 3480.469 34804.69 34.80469 58.00781 
                66.40625 
 
1:3:3 B3 BATCH 
time Abs slope intercept conc conc*900 conc*10 conc/1000 %drug release 
5 0.6523 0.064 0.28 5.817188 5235.469 52354.69 52.35469 87.25781 
10 0.5776 0.064 0.28 4.65 4185 41850 41.85 69.75 
15 0.554 0.064 0.28 4.28125 3853.125 38531.25 38.53125 64.21875 
30 0.5213 0.064 0.28 3.770313 3393.281 33932.81 33.93281 56.55469 
45 0.5473 0.064 0.28 4.176563 3758.906 37589.06 37.58906 62.64844 
60 0.5275 0.064 0.28 3.867188 3480.469 34804.69 34.80469 58.00781 
        
66.40625 
 
1:4:4 (best batch) B4 BATCH 
Time Abs slope intercept conc conc*900 conc*10 conc/1000 %drug release 
5 0.5844 0.064 0.28 4.75625 4280.625 42806.25 42.80625 71.34375 
10 0.633 0.064 0.28 5.515625 4964.063 49640.63 49.64063 82.73438 
15 0.5949 0.064 0.28 4.920313 4428.281 44282.81 44.28281 73.80469 
30 0.654 0.064 0.28 5.84375 5259.375 52593.75 52.59375 87.65625 
45 0.6648 0.064 0.28 6.0125 5411.25 54112.5 54.1125 90.1875 
60 0.6665 0.064 0.28 6.039063 5435.156 54351.56 54.35156 90.58594 
        
82.71875 
 
1:5:5 B5 BATCH 
Time Abs Slope intercept conc conc*900 conc*10 conc/1000 %drug release 
5 0.487 0.064 0.28 3.234375 2910.938 29109.38 29.10938 48.51563 
10 0.554 0.064 0.28 4.28125 3853.125 38531.25 38.53125 64.21875 
15 0.654 0.064 0.28 5.84375 5259.375 52593.75 52.59375 87.65625 
30 0.6786 0.064 0.28 6.228125 5605.313 56053.13 56.05313 93.42188 
45 0.698 0.064 0.28 6.53125 5878.125 58781.25 58.78125 97.96875 
60 0.699 0.064 0.28 6.546875 5892.188 58921.88 58.92188 98.20313 
        
81.66406 
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C1 BATCH 
PEG6000: 
POLOXAMER 407 
1:1:1 
       
Time abs slope intercept conc conc*900 conc*10 conc/1000 %drug release 
5 0.432 0.064 0.28 2.375 2137.5 21375 21.375 35.625 
10 0.4453 0.064 0.28 2.582813 2324.531 23245.31 23.24531 38.74219 
15 0.4567 0.064 0.28 2.760938 2484.844 24848.44 24.84844 41.41406 
30 0.5564 0.064 0.28 4.31875 3886.875 38868.75 38.86875 64.78125 
45 0.5876 0.064 0.28 4.80625 4325.625 43256.25 43.25625 72.09375 
60 0.6547 0.064 0.28 5.854688 5269.219 52692.19 52.69219 87.82031 
        
56.74609 
 
1:2:2 C2 BATCH 
Time Abs slope intercept conc conc*900 conc*10 conc/1000 %drug release 
5 0.5162 0.064 0.28 3.690625 3321.563 33215.63 33.21563 55.35938 
10 0.5072 0.064 0.28 3.55 3195 31950 31.95 53.25 
15 0.5006 0.064 0.28 3.446875 3102.188 31021.88 31.02188 51.70313 
30 0.316 0.064 0.28 0.5625 506.25 5062.5 5.0625 8.4375 
45 0.7123 0.064 0.28 6.754688 6079.219 60792.19 60.79219 101.3203 
60 0.7311 0.064 0.28 7.048438 6343.594 63435.94 63.43594 105.7266 
        
62.63281 
 
1:3:3 C3 BATCH 
Time Abs slope intercept conc conc*900 conc*10 conc/1000 %drug release 
5 0.4563 0.064 0.28 2.754688 2479.219 24792.19 24.79219 41.32031 
10 0.4876 0.064 0.28 3.24375 2919.375 29193.75 29.19375 48.65625 
15 0.4897 0.064 0.28 3.276563 2948.906 29489.06 29.48906 49.14844 
30 0.564 0.064 0.28 4.4375 3993.75 39937.5 39.9375 66.5625 
45 0.6753 0.064 0.28 6.176563 5558.906 55589.06 55.58906 92.64844 
60 0.6897 0.064 0.28 6.401563 5761.406 57614.06 57.61406 96.02344 
        
65.72656 
 
1:4:4 C5 BATCH 
Time Abs slope intercept conc conc*900 conc*10 conc/1000 %drug release 
5 0.5432 0.064 0.28 4.1125 3701.25 37012.5 37.0125 61.6875 
10 0.5543 0.064 0.28 4.285938 3857.344 38573.44 38.57344 64.28906 
15 0.5546 0.064 0.28 4.290625 3861.563 38615.63 38.61563 64.35938 
30 0.5687 0.064 0.28 4.510938 4059.844 40598.44 40.59844 67.66406 
45 0.681 0.064 0.28 6.265625 5639.063 56390.63 56.39063 93.98438 
60 0.7011 0.064 0.28 6.579688 5921.719 59217.19 59.21719 98.69531 
        
75.11328 
 
1:5:5 C6 BATCH 
Time Abs slope intercept conc conc*900 conc*10 conc/1000 % drug release 
5 0.5342 0.064 0.28 3.971875 3574.688 35746.88 35.74688 59.57813 
10 0.5674 0.064 0.28 4.490625 4041.563 40415.63 40.41563 67.35938 
15 0.6543 0.064 0.28 5.848438 5263.594 52635.94 52.63594 87.72656 
30 0.6675 0.064 0.28 6.054688 5449.219 54492.19 54.49219 90.82031 
45 0.6786 0.064 0.28 6.228125 5605.313 56053.13 56.05313 93.42188 
60 0.689 0.064 0.28 6.390625 5751.563 57515.63 57.51563 95.85938 
        
82.46094 
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Fig 2: % drug release of furosemide: poloxamer 407:pvpk30.(1:4:4) 
4) X-ray diffraction:- 
The x-ray diffraction pattern of furosemide exhibited sharp, highly intense and less diffused peaks indicating the 
crystalline nature of drug, as shown in Figure. It showed diffraction peaks at 2θ degree. However the x-ray diffraction 
patterns of the physical mixture and solid dispersion were simply a superimposition of each component with with respect to 
the peaks of frusemide. Moreover, the relative intensity and 2θ angle of these peaks remained practically unchanged. Thus, 
there was no amorphization of the drug and which still retained its original crystalline form. 
 
 
Fig 3: XRD spectra of solid dispersion. 
 
 
 
Figure 4: X-ray diffraction spectra of best formulation (F4) 
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5) DSC spectra of best formulation 
 
 
Figure 5: DSC Spectra of furosemide pure drug. 
 
Figure 6: DSC Spectra of furosemide solid dispersion (F4) 
 
DSC thermograms of furosemide and Solid dispersion of furosemide (F4, Poloxamer 407:PVPK30 1:4:4), in 
Figure 7 and 8 respectively. DSC studies, on the basis of the melting peak of furosemide solid dispersion (213.23 
o
C), 
indicate that there was not interaction between the drug and carrier. However, the characteristic melting peak of solid 
dispersion slightly shifted toward a higher temperature. This may be attributed to high polymer concentration and uniform 
distribution of the drug in the crust of the polymer, resulting in complete miscibility of the drug in the polymer. The 
similarity in the DSC of the Pure drug and solid dispersion suggests that the solvent evaporation method did not induce 
interaction at the molecular level. 
6) Fourier Transform Infrared (FTIR) Spectroscopy 
FTIR spectra were recorded on samples prepared in potassium bromide (KBr) disks. Samples were prepared in 
KBr disks by means of a hydrostatic press at 6-8 tons pressure. The scanning range was 500 to 4000 cm -1. IR spectra of 
FRMD and its binary systems with PEG-4000 are presented in Figure. Pure Furosemide spectra showed sharp characteristic 
peaks at 3400.27, 3122.54, 1665, and 1560 cm–1. All the above characteristic peaks appear in the spectra of all binary 
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systems at same wave number indicating no modification or interaction between the drug and carrier. The FTIR of FRMD, 
PM and SD (1:5) was given in figure 7. 
 
Figure 7: FTIR of furosemide and solid dispersion. 
 
4. Conclusion 
The objective of the present study was to improve the solubility and dissolution behaviour of the poorly soluble 
drug, furosemide by solid dispersion technique using PEG 6000 and Poloxamer 407 as carrier. Solid dispersion of 
furosemide prepared by a Solvent evaporation method showed significantly higher drug solubility in comparison with pure 
drug. FTIR and DSC studies showed no evidence of interaction between the drug and carrier. XRD study shows 
amorphization of drug. Out of the 15 prepared formulation SSD- B4 showed marked increase in the solubility as well as the 
dissolution when compared to pure drug. Thus it can be concluded that the solubility of the poorly soluble drug, furosemide  
can be improved markedly by using solid dispersion technique and the carrier Poloxamer 407  and  PVPK30 has increased 
the dissolution of the drug without any interaction. 
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